文献速递免疫规划卫生政策与健康促进

低收入和中等收入国家人乳头瘤病毒疫苗接种交付成本:系统综述

Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
PubMed 文献 · Vaccine · 2024-02-01

该研究系统检索2005至2023年低收入和中等收入国家HPV疫苗接种交付成本文献,纳入15项研究,多数来自非洲国家且在试点或示范阶段开展;每剂财务成本为0.31至24.07美元,经济成本为1.48至48.70美元,成本随国家和实施阶段差异较大。

要点

  • 纳入15项研究,64%来自非洲国家,60%在试点或示范阶段开展成本核算。
  • 每剂财务成本0.31至24.07美元,经济成本1.48至48.70美元,已换算为2022年美元。
  • 多数研究未描述报告交付成本的不确定性。

核心结论

  • HPV疫苗接种交付成本因国家和成本核算时所处实施阶段不同而差异很大。
  • 作者提出进一步研究领域包括项目超出引入阶段后的成本核算以及非洲以外低收入和中等收入国家的成本核算。

研究设计与样本

  • 系统综述,检索2005至2023年发表的低收入和中等收入国家HPV疫苗接种交付成本文献,采用PICO框架制定纳入标准。
  • 共识别226条记录,15项报告原始成本数据和单位成本的研究纳入分析。
  • 单位成本换算为2022年美元以便比较,并采用改编框架进行批判性评价,该框架包括卫生经济学评价报告统一标准(CHEERS)条目和世界卫生组织(WHO)主导的疫苗交付成本核算共识声明等。

主要发现

  • 多数研究(64%)在非洲国家开展,60%在HPV疫苗试点或示范阶段进行成本核算。
  • 每剂财务成本范围为0.31至24.07美元,每剂经济成本范围为1.48至48.70美元。
  • 批判性评价显示多数研究未描述所报告交付成本的不确定性。

局限性

  • 多数研究未描述所报告交付成本的不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines to protect against human papillomavirus (HPV) infection are recommended for all adolescents by the World Health Organization (WHO) and are primarily delivered in school-based settings. This systematic review aims to summarize the available evidence on the cost of HPV vaccine delivery in low- and middle-income countries (LMICs). This updated evidence is eminent given recent global efforts to revitalize HPV vaccine delivery following the COVID-19 pandemic and can be used to inform planning for program sustainability. We carried out a systematic review of published literature reporting the costs of HPV vaccine delivery in LMICs published between 2005 and 2023. Eligibility criteria were developed using the Population, Intervention, Comparator, Outcome (PICO) framework, and studies that reported primary costing data and unit costs of HPV vaccine delivery were included. From the included studies, we extracted data such as phase of HPV vaccine implementation when costing was done, delivery strategy, and unit costs. Unit costs were converted into 2022 US$ for comparability. All included studies underwent critical appraisal using an adapted framework including Consolidated Health Economics Evaluation Reporting Standards criteria, the WHO-led consensus statement on vaccine delivery costing, and other frameworks. Our research identified 226 records, of which 15 met our inclusion criteria. Most studies (64 %) were carried out in African countries and during HPV vaccine pilots or demonstrations (60 %). Vaccine delivery cost ranged from $0.31 to $24.07 per dose for financial costs and $1.48 to $48.70 per dose for economic costs. The critical appraisal showed that most studies did not describe the uncertainty of reported delivery cost. Our systematic review evidence suggests that HPV vaccine delivery costs vary widely depending on country and stage of implementation when costing was done. Areas for further research include costing when programs are beyond the introduction phase and in LMICs outside of Africa.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Slavkovsky R, Callen E, Pecenka C, et al. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review. Vaccine. 2024. PMID: 38302338. doi:10.1016/j.vaccine.2024.01.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。